Key facts
- Osteal Therapeutics’s last known valuation is $575.6M (Nov 2025).
- It has raised $133.1M across 4 recorded rounds; the latest was Early Stage VC ($15.6M) in Oct 2025.
- Notable investors include Johnson & Johnson JJDC, Asteroid Partners, GOS Capital, Gideon Strategic Partners, HM Capital — 9 tracked in total.
- Osteal Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently Jun 2024 ($50.0M sold to 16 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Osteal Therapeutics
Funding rounds
4 roundsAbout Osteal Therapeutics
Developer of infection therapeutics designed to reduce the mortality, morbidity, and cost of care associated with musculoskeletal infections. The company's therapeutics offers a drug and device combination product to treat orthopedic infections, infected joint prosthesis, and their consequences, and provide a fast and reliable treatment option, enabling orthopedic surgeons to offer an effective treatment for musculoskeletal diseases.
- Sector
- Healthcare
- HQ
- Dallas, TX, United States
- Founded
- 2013
- Employees
- 49
- Website
- ostealtx.com/
- Ownership
- Privately Held (backing)
Osteal Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Osteal Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Osteal Therapeutics in its N-PORT filings yet. We sweep new filings monthly.